Nageshwar R. Budha, Ph.D.
Affiliations: | 2009 | Pharmaceutical Sciences | University of Tennessee Health Science Center, Memphis, TN, United States |
Area:
Pharmacology, Pharmaceutical ChemistryGoogle:
"Nageshwar Budha"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Bernd Meibohm | grad student | 2009 | UTHSC | |
| (A pharmacokinetics and pharmacodynamics (PK/PD) guided approach to lead optimization of nitrofuranylamide anti-tuberculosis agents.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Saura C, Roda D, Roselló S, et al. (2016) A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors. Cancer Discovery |
| Budha NR, Ji T, Musib L, et al. (2016) Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clinical Pharmacokinetics |
| Tolcher A, Bendell JC, Papadopoulos KP, et al. (2016) A PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF CUDC-427, A POTENT, ORAL, MONOVALENT IAP ANTAGONIST, IN PATIENTS WITH REFRACTORY SOLID TUMORS. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Bonate PL, Ahamadi M, Budha N, et al. (2016) Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics |
| Chen Y, Ma F, Lu T, et al. (2015) Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Clinical Pharmacokinetics |
| Han K, Jin JY, Marchand M, et al. (2015) Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology |
| Budha NR, Leabman M, Jin JY, et al. (2015) Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. The Aaps Journal. 17: 881-90 |
| Peng K, Xu K, Liu L, et al. (2014) Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study. Mabs. 6: 1500-8 |
| Yago MR, Frymoyer A, Benet LZ, et al. (2014) The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. The Aaps Journal. 16: 1358-65 |
| Smelick GS, Heffron TP, Chu L, et al. (2013) Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Molecular Pharmaceutics. 10: 4055-62 |